Medicare Rx Plan Price Reviews By CMS Are “Appropriate,” MedPAC Says
This article was originally published in The Pink Sheet Daily
CMS would not set drug prices or an average discount across a group of drugs, Medicare Payment Advisory Commission notes in comments on Part D regs. MedPAC also supports use of drug price benchmark for Part D “fallback” plans.
You may also be interested in...
The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.